Belvedere Trading
FULC icon

Belvedere Trading’s Fulcrum Therapeutics FULC Stock Holding History

Belvedere Trading’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-758
Closed -$3.56K – 773
2024
Q4 		$3.56K Buy
+758
New +$2.8K ﹤0.01% 767
2024
Q3 		– Sell
-3,988
Closed -$29.6K – 773
2024
Q2 		$24.7K Buy
+3,988
New +$30.2K ﹤0.01% 557
2022
Q2 		– Sell
-15,785
Closed -$201K – 432
2022
Q1 		$201K Buy
+15,785
New +$223K 0.01% 244

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's FULC Position: Q1 2025 in Review

Belvedere Trading sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 758 shares — an estimated $3.56K sold.

Belvedere Trading first reported a position in FULC in Q1 2022 and held it in 3 quarters. The position peaked at $201K in Q1 2022. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

  • Belvedere Trading reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Belvedere Trading sold 758 Fulcrum Therapeutics shares in Q1 2025, an estimated $3.56K.
  • Belvedere Trading first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 3 quarters.
  • Belvedere Trading's Fulcrum Therapeutics position peaked at $201K in Q1 2022.
  • 117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on Belvedere Trading's 13F filing for Q1 2025, filed 9 May 2025.